Cilengitide

Also called: EMD 121974; EMD121974

What it is

An investigational cyclic RGD integrin inhibitor; its phase 3 glioblastoma trial failed.

Approval status

In Clinical Trials. Not approved anywhere. The phase 3 CENTRIC trial (545 patients, 2014) found no overall survival benefit, and the phase 2 CORE trial also missed its primary endpoint (PubMed abstracts, read October 3, 2026).

Dosing, as printed in the page's Recommended Dosing box

Used in human trials

No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.

Protocol and source	Dose	Frequency	Duration	Route
Trial: CENTRIC (methylated MGMT glioblastoma) **[Human study]** PMID 25163906	2,000 mg	Twice weekly	With temozolomide ch emoradiotherapy	Intravenous
Trial: CORE intensive arm (unmethylated MGMT) **[Human study]** PMID 25762461	2,000 mg	5 times weekly in weeks 1 to 6, then twice weekly	With chemoradiot herapy and maintenance	Intravenous

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for "research use only" are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

Key human evidence

The first 3 of the 13 human studies carded on the page (16 study cards in all):

- **CENTRIC phase 3** (Human, 2014). In 545 patients with MGMT-methylated glioblastoma, median overall survival was 26.3 months with cilengitide and 26.3 months without (hazard ratio 1.02, p = 0.86); no subgroup benefited and no additional toxicity was seen. **PMID 25163906**
- **CORE: unmethylated tumours** (Human, 2015). Median overall survival was 16.3 months with standard cilengitide (HR 0.686, p = 0.032) and 14.5 months with intensive cilengitide against 13.4 months for controls; cilengitide was well tolerated. **PMID 25762461**
- **Recurrent glioblastoma phase 2** (Human, 2008). In 81 patients, cilengitide had an excellent safety profile; activity trended better at 2,000 mg, with 6-month progression-free survival of 15% and median survival of 9.9 months. **PMID 18981465**

Interactions

A PubMed search for interaction studies of this compound with any drug (October 3, 2026, 6 records) found none in people. That is not evidence that it is safe to combine with anything.

Side effects and cautions

Reported side effects	Contraindications and cautions
• No additional toxicity over standard treatment in CENTRIC • Lymphopenia and thrombocytopenia occurred in both arms	• Not approved for any use

Five questions to ask

1. Cilengitide is listed here as "In Clinical Trials". What does the evidence on this sheet mean for someone in my situation, and is there an approved treatment I should consider instead?
2. Here are the medicines and supplements I take. Do any of them interact with Cilengitide? This sheet records none published, which does not mean none exist.
3. Which side effects should make me stop and call you, for example no additional toxicity over standard treatment in centric?
4. Do any of the cautions on this sheet apply to me, such as: Not approved for any use?
5. What should we check before I start and while I am on it (blood tests, blood pressure, weight), and how often?

Grey Peptides is a vendor-neutral encyclopedia: it sells nothing and names no seller. This sheet is educational, not medical advice, and is not a prescription.